Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) Treatment for First-Line Therapy  of Patients with CLL with Mutated IGHV and Without Deletion 17p

CLL, Chemotherapy, Ibrutinib, Frontline Treatment, Mutated IGHV

Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Authors: Nitin Jain, Philip Thompson, Jan Burger, Gautam Borthakur, Prithviraj Bose, Zeev Estrov, Alessandra Ferrajoli, Koichi Takahashi, Naveen Garg, Xuemei Wang, Varsha Gandhi, William Plunkett, Rashmi Kanagal-Shamanna, Keyur Patel, Wanda Lopez, Hagop Kantarjian Source Type: research